$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Pro Medicus Ltd (ASX: PME) and CSL Ltd (ASX: CSL) shares are among the most heavily traded S&P/ASX 200 Index (ASX: XJO) healthcare shares.

But they've delivered some very disparate returns over the past three years.

One of the ASX healthcare juggernauts has smashed the 22.4% returns delivered by the ASX 200 since 22 September 2023, while the other materially trails that performance.

So, if you'd bought $10,000 worth of Pro Medicus and CSL shares three years ago, how much would you have now?

I'm glad you asked!

Two scientists analysing results on a computer screen.

Image source: Getty Images

Tipping $10,000 into CSL shares

On 22 September, shares in the ASX 200 biotech giant closed the day trading for $252.15 each.

Meaning for $10,000 you could have bought 39 CSL shares, with enough change left over to take your partner out to dinner. For the next 10 or so months, you would have watched those shares march higher.

But by August 2024, the ASX 200 healthcare share came under sustained selling pressure.

On Thursday, CSL shares were swapping hands for $179.09 apiece. Meaning those 39 shares you bought three years ago for $10,000 would be worth $6,985 today.

Now, we shouldn't entirely discount the CSL dividends.

If you owned the stock for the past three years you would have received (or shortly will) the past six unfranked dividend payments, totalling $12.55 a share. CSL stock traded ex-dividend on 9 September. If you owned shares at market close on 8 September, you can expect to receive the final FY 2026 dividend of $2.244 a share on 2 October.

So, if we add that $12.55 of passive income back into the recent share price, then the accumulated value of the CSL shares you bought three years ago is now worth $191.64. And the 39 shares you invested $10,000 into are worth $7,474.

Which brings us to…

Buying Pro Medicus shares in September 2023

Three years ago, shares in the ASX 200 health imaging company closed the day trading for $71.67 apiece.

Meaning your $10,000 investment would have netted you 139 shares, with enough change for popcorn and a movie.

On Thursday, Pro Medicus shares were changing hands for $159.52 each. So those 139 shares are worth $22,173 today.

And, as with CSL shares, you'd also have received (or shortly will) the last six fully franked Pro Medicus dividend payments, totalling $1.64 a share. Pro Medicus stock traded ex-dividend on 7 September. If you owned shares on 4 September, you can expect that record high 37 cent per share final dividend to land in your bank account on 29 September.

Now, if we add that passive income back into the recent share price, then the accumulated value of the 139 Pro Medicus shares you bought three years ago for $10,000 is now worth $22,401.

Which sees Pro Medicus clearly top CSL shares as the better investment over the past three years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »